InvestorsHub Logo
Followers 7
Posts 264
Boards Moderated 0
Alias Born 01/08/2013

Re: None

Thursday, 08/11/2016 12:28:32 PM

Thursday, August 11, 2016 12:28:32 PM

Post# of 4794
Todays DEA refusal to reclassify marijuana has been tumultuous for CBDS but recent news points to refuting the sturid decision...

While the United States government refuses to admit the cannabis plant has any real medicinal benefit, its position has not prevented federal health agencies, over the years, from approving synthetic versions of the herb’s psychoactive component to be used by Big Pharma in the treatment of serious conditions.

In fact, the U.S. Food and Drug Administration (FDA), one of the primary barriers in the grand scheme of nationwide legalization, recently approved a liquid variety of synthetic tetrahydrocannabidiol (THC) that will be sold to people suffering from AIDS and cancer.

It was revealed earlier this month that Insys Therapeutics is gearing up to go after a piece of the medical marijuana market, one reportedly worth hundreds of millions of dollars, with a new FDA-approved form of dronabinol. This first-of-a-kind liquid THC synthetic, set to be stocked on pharmacy shelves under the name Syndros, has been given the green light for the treatment of “anorexia associated with weight loss in patients with AIDS, and nausea and vomiting associated with cancer chemotherapy in patients who have failed to respond adequately to conventional antiemetic treatments.”
Volume:
Day Range:
Bid:
Ask:
Last Trade Time:
Total Trades:
  • 1D
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y
Recent CBDS News